Advertisement

 

 

Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism.

Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism.
Author Information (click to view)

Giakoumis M, Tsioufis C, Dimitriadis K, Sonikian M, Kasiakogias A, Andrikou E, Kalos T, Konstantinidis D, Filis K, Petras D, Tousoulis D,


Giakoumis M, Tsioufis C, Dimitriadis K, Sonikian M, Kasiakogias A, Andrikou E, Kalos T, Konstantinidis D, Filis K, Petras D, Tousoulis D, (click to view)

Giakoumis M, Tsioufis C, Dimitriadis K, Sonikian M, Kasiakogias A, Andrikou E, Kalos T, Konstantinidis D, Filis K, Petras D, Tousoulis D,

Advertisement

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018 01 03() pii S1109-9666(17)30504-3
Abstract
BACKGROUND
Arterial stiffness is linked to the progression of atherosclerosis, while activation of vitamin D receptor exerts favorable cardiovascular effects in patients with renal insufficiency. In this study, we investigated the effects of oral treatment with paricalcitol, a potent vitamin D receptor activator on arterial stiffness and osteopontin, a marker of atherosclerosis, in hypertensive patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.

METHODS
We followed up 29 treated hypertensive patients (mean age 74.1 years, 19 men, office blood pressure=132/85mmHg) with CKD stages 3-5 [mean glomerular filtration rate (GFR)=19.4 ml/min/1.73m2], who were on therapy with oral paricalcitol for 1 year. The control group consisted of 10 age, sex and GFR matched hypertensives with secondary hyperparathyroidism.

RESULTS
After 1 year of treatment with paricalcitol compared to baseline there was no statistical difference in levels of GFR, office blood pressure and osteopontin (p=NS for all), while carotid-femoral PWV was reduced from 11.8±2.6 m/sec to 11.2±2.4 m/sec (p<0.05). The control group exhibited no significant changes in carotid-femoral PWV (p=NS). CONCLUSIONS
Treatment with oral paricalcitol in hypertensive subjects suffering from CKD stages 3-5 and secondary hyperparathyroidism is accompanied by amelioration of arterial stiffness as reflected by the reduction of carotid-femoral PWV.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − twelve =

[ HIDE/SHOW ]